Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore,...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical health care and sciences 2016-06, Vol.2 (1), p.14-14, Article 14 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 14 |
| container_title | Journal of pharmaceutical health care and sciences |
| container_volume | 2 |
| creator | Abe, Junko Umetsu, Ryogo Mataki, Kanako Kato, Yamato Ueda, Natsumi Nakayama, Yoko Hane, Yuuki Matsui, Toshinobu Hatahira, Haruna Sasaoka, Sayaka Motooka, Yumi Hara, Hideaki Kato, Zenichiro Kinosada, Yasutomi Inagaki, Naoki Nakamura, Mitsuhiro |
| description | Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER) database and analyze the time-to-onset profile of SJS/TEN.
We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with SJS/TEN.
The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the 0-19-, 20-39-, 60-79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 % confidence interval [CI], 1.21-1.45), 1.78 (95 % CI, 1.65-1.93), 0.71 (95 % CI, 0.66-0.75), and 0.72 (95 % CI, 0.66-0.79), respectively. The adjusted ROR tended to be higher in patients aged 0-19 years, particularly in patients using antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment. The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and corticosteroids.
Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics is important. These drugs should be used and monitored within the first 2-3 days of treatment in the Japanese population. |
| doi_str_mv | 10.1186/s40780-016-0048-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4915172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A469989146</galeid><sourcerecordid>A469989146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-41ab4a587511884a0d48ebf89e8e6d9dfc7ea7fdf107e4b3e64717c15646d2833</originalsourceid><addsrcrecordid>eNptkl9vFCEUxSdGY5vaD-CLIfHFl6kww795MdnUVm2aNKn6TBi47NLMwAgzG_fbl83W2hrDwyXwOwcunKp6S_AZIZJ_zBQLiWtMeI0xlTV7UR03mLEaNx19-WR-VJ3mfIcxJkxQKsXr6qgRbYtlw46r3SroYZd9RtGh7zNsIeT6Km5CjgHlXbApjoB0sGiOv71BMHkLadQDCmBSPEiX7MMazRtAV3rSATKgld1CKvVzWtboorjO6BammGZk9ax7neFN9crpIcPpQz2pfl5e_Dj_Wl_ffPl2vrquDeN4rinRPdVMCla6llRjSyX0TnYggdvOOiNAC2cdwQJo3wKngghDGKfcNrJtT6pPB99p6Uewplwl6UFNyY867VTUXj3fCX6j1nGraEcYEU0x-PBgkOKvBfKsRp8NDEPpNC5ZEdF1DWm47Ar6_h_0Li6pvHChJMYFlIT-pdZ6AOWDi-VcszdVK8oL0xHKC3X2H6oMC6M3MYDzZf2ZgBwE5V9yTuAeeyRY7SOjDpFRJTJqHxnFiubd08d5VPwJSHsPEBS82g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1800799814</pqid></control><display><type>article</type><title>Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database</title><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Abe, Junko ; Umetsu, Ryogo ; Mataki, Kanako ; Kato, Yamato ; Ueda, Natsumi ; Nakayama, Yoko ; Hane, Yuuki ; Matsui, Toshinobu ; Hatahira, Haruna ; Sasaoka, Sayaka ; Motooka, Yumi ; Hara, Hideaki ; Kato, Zenichiro ; Kinosada, Yasutomi ; Inagaki, Naoki ; Nakamura, Mitsuhiro</creator><creatorcontrib>Abe, Junko ; Umetsu, Ryogo ; Mataki, Kanako ; Kato, Yamato ; Ueda, Natsumi ; Nakayama, Yoko ; Hane, Yuuki ; Matsui, Toshinobu ; Hatahira, Haruna ; Sasaoka, Sayaka ; Motooka, Yumi ; Hara, Hideaki ; Kato, Zenichiro ; Kinosada, Yasutomi ; Inagaki, Naoki ; Nakamura, Mitsuhiro</creatorcontrib><description>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER) database and analyze the time-to-onset profile of SJS/TEN.
We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with SJS/TEN.
The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the 0-19-, 20-39-, 60-79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 % confidence interval [CI], 1.21-1.45), 1.78 (95 % CI, 1.65-1.93), 0.71 (95 % CI, 0.66-0.75), and 0.72 (95 % CI, 0.66-0.79), respectively. The adjusted ROR tended to be higher in patients aged 0-19 years, particularly in patients using antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment. The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and corticosteroids.
Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics is important. These drugs should be used and monitored within the first 2-3 days of treatment in the Japanese population.</description><identifier>ISSN: 2055-0294</identifier><identifier>EISSN: 2055-0294</identifier><identifier>DOI: 10.1186/s40780-016-0048-5</identifier><identifier>PMID: 27330825</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Age factors in disease ; Development and progression ; Drug therapy ; Evaluation ; Observations ; Pharmaceuticals ; Practice guidelines (Medicine) ; Stevens-Johnson syndrome ; Toxic epidermal necrolysis</subject><ispartof>Journal of pharmaceutical health care and sciences, 2016-06, Vol.2 (1), p.14-14, Article 14</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-41ab4a587511884a0d48ebf89e8e6d9dfc7ea7fdf107e4b3e64717c15646d2833</citedby><cites>FETCH-LOGICAL-c560t-41ab4a587511884a0d48ebf89e8e6d9dfc7ea7fdf107e4b3e64717c15646d2833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915172/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915172/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27330825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abe, Junko</creatorcontrib><creatorcontrib>Umetsu, Ryogo</creatorcontrib><creatorcontrib>Mataki, Kanako</creatorcontrib><creatorcontrib>Kato, Yamato</creatorcontrib><creatorcontrib>Ueda, Natsumi</creatorcontrib><creatorcontrib>Nakayama, Yoko</creatorcontrib><creatorcontrib>Hane, Yuuki</creatorcontrib><creatorcontrib>Matsui, Toshinobu</creatorcontrib><creatorcontrib>Hatahira, Haruna</creatorcontrib><creatorcontrib>Sasaoka, Sayaka</creatorcontrib><creatorcontrib>Motooka, Yumi</creatorcontrib><creatorcontrib>Hara, Hideaki</creatorcontrib><creatorcontrib>Kato, Zenichiro</creatorcontrib><creatorcontrib>Kinosada, Yasutomi</creatorcontrib><creatorcontrib>Inagaki, Naoki</creatorcontrib><creatorcontrib>Nakamura, Mitsuhiro</creatorcontrib><title>Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database</title><title>Journal of pharmaceutical health care and sciences</title><addtitle>J Pharm Health Care Sci</addtitle><description>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER) database and analyze the time-to-onset profile of SJS/TEN.
We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with SJS/TEN.
The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the 0-19-, 20-39-, 60-79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 % confidence interval [CI], 1.21-1.45), 1.78 (95 % CI, 1.65-1.93), 0.71 (95 % CI, 0.66-0.75), and 0.72 (95 % CI, 0.66-0.79), respectively. The adjusted ROR tended to be higher in patients aged 0-19 years, particularly in patients using antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment. The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and corticosteroids.
Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics is important. These drugs should be used and monitored within the first 2-3 days of treatment in the Japanese population.</description><subject>Age factors in disease</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Evaluation</subject><subject>Observations</subject><subject>Pharmaceuticals</subject><subject>Practice guidelines (Medicine)</subject><subject>Stevens-Johnson syndrome</subject><subject>Toxic epidermal necrolysis</subject><issn>2055-0294</issn><issn>2055-0294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkl9vFCEUxSdGY5vaD-CLIfHFl6kww795MdnUVm2aNKn6TBi47NLMwAgzG_fbl83W2hrDwyXwOwcunKp6S_AZIZJ_zBQLiWtMeI0xlTV7UR03mLEaNx19-WR-VJ3mfIcxJkxQKsXr6qgRbYtlw46r3SroYZd9RtGh7zNsIeT6Km5CjgHlXbApjoB0sGiOv71BMHkLadQDCmBSPEiX7MMazRtAV3rSATKgld1CKvVzWtboorjO6BammGZk9ax7neFN9crpIcPpQz2pfl5e_Dj_Wl_ffPl2vrquDeN4rinRPdVMCla6llRjSyX0TnYggdvOOiNAC2cdwQJo3wKngghDGKfcNrJtT6pPB99p6Uewplwl6UFNyY867VTUXj3fCX6j1nGraEcYEU0x-PBgkOKvBfKsRp8NDEPpNC5ZEdF1DWm47Ar6_h_0Li6pvHChJMYFlIT-pdZ6AOWDi-VcszdVK8oL0xHKC3X2H6oMC6M3MYDzZf2ZgBwE5V9yTuAeeyRY7SOjDpFRJTJqHxnFiubd08d5VPwJSHsPEBS82g</recordid><startdate>20160621</startdate><enddate>20160621</enddate><creator>Abe, Junko</creator><creator>Umetsu, Ryogo</creator><creator>Mataki, Kanako</creator><creator>Kato, Yamato</creator><creator>Ueda, Natsumi</creator><creator>Nakayama, Yoko</creator><creator>Hane, Yuuki</creator><creator>Matsui, Toshinobu</creator><creator>Hatahira, Haruna</creator><creator>Sasaoka, Sayaka</creator><creator>Motooka, Yumi</creator><creator>Hara, Hideaki</creator><creator>Kato, Zenichiro</creator><creator>Kinosada, Yasutomi</creator><creator>Inagaki, Naoki</creator><creator>Nakamura, Mitsuhiro</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160621</creationdate><title>Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database</title><author>Abe, Junko ; Umetsu, Ryogo ; Mataki, Kanako ; Kato, Yamato ; Ueda, Natsumi ; Nakayama, Yoko ; Hane, Yuuki ; Matsui, Toshinobu ; Hatahira, Haruna ; Sasaoka, Sayaka ; Motooka, Yumi ; Hara, Hideaki ; Kato, Zenichiro ; Kinosada, Yasutomi ; Inagaki, Naoki ; Nakamura, Mitsuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-41ab4a587511884a0d48ebf89e8e6d9dfc7ea7fdf107e4b3e64717c15646d2833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age factors in disease</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Evaluation</topic><topic>Observations</topic><topic>Pharmaceuticals</topic><topic>Practice guidelines (Medicine)</topic><topic>Stevens-Johnson syndrome</topic><topic>Toxic epidermal necrolysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abe, Junko</creatorcontrib><creatorcontrib>Umetsu, Ryogo</creatorcontrib><creatorcontrib>Mataki, Kanako</creatorcontrib><creatorcontrib>Kato, Yamato</creatorcontrib><creatorcontrib>Ueda, Natsumi</creatorcontrib><creatorcontrib>Nakayama, Yoko</creatorcontrib><creatorcontrib>Hane, Yuuki</creatorcontrib><creatorcontrib>Matsui, Toshinobu</creatorcontrib><creatorcontrib>Hatahira, Haruna</creatorcontrib><creatorcontrib>Sasaoka, Sayaka</creatorcontrib><creatorcontrib>Motooka, Yumi</creatorcontrib><creatorcontrib>Hara, Hideaki</creatorcontrib><creatorcontrib>Kato, Zenichiro</creatorcontrib><creatorcontrib>Kinosada, Yasutomi</creatorcontrib><creatorcontrib>Inagaki, Naoki</creatorcontrib><creatorcontrib>Nakamura, Mitsuhiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of pharmaceutical health care and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abe, Junko</au><au>Umetsu, Ryogo</au><au>Mataki, Kanako</au><au>Kato, Yamato</au><au>Ueda, Natsumi</au><au>Nakayama, Yoko</au><au>Hane, Yuuki</au><au>Matsui, Toshinobu</au><au>Hatahira, Haruna</au><au>Sasaoka, Sayaka</au><au>Motooka, Yumi</au><au>Hara, Hideaki</au><au>Kato, Zenichiro</au><au>Kinosada, Yasutomi</au><au>Inagaki, Naoki</au><au>Nakamura, Mitsuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database</atitle><jtitle>Journal of pharmaceutical health care and sciences</jtitle><addtitle>J Pharm Health Care Sci</addtitle><date>2016-06-21</date><risdate>2016</risdate><volume>2</volume><issue>1</issue><spage>14</spage><epage>14</epage><pages>14-14</pages><artnum>14</artnum><issn>2055-0294</issn><eissn>2055-0294</eissn><abstract>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER) database and analyze the time-to-onset profile of SJS/TEN.
We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with SJS/TEN.
The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the 0-19-, 20-39-, 60-79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 % confidence interval [CI], 1.21-1.45), 1.78 (95 % CI, 1.65-1.93), 0.71 (95 % CI, 0.66-0.75), and 0.72 (95 % CI, 0.66-0.79), respectively. The adjusted ROR tended to be higher in patients aged 0-19 years, particularly in patients using antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment. The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and corticosteroids.
Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics is important. These drugs should be used and monitored within the first 2-3 days of treatment in the Japanese population.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27330825</pmid><doi>10.1186/s40780-016-0048-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2055-0294 |
| ispartof | Journal of pharmaceutical health care and sciences, 2016-06, Vol.2 (1), p.14-14, Article 14 |
| issn | 2055-0294 2055-0294 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4915172 |
| source | DOAJ Directory of Open Access Journals; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Age factors in disease Development and progression Drug therapy Evaluation Observations Pharmaceuticals Practice guidelines (Medicine) Stevens-Johnson syndrome Toxic epidermal necrolysis |
| title | Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T13%3A15%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20Stevens-Johnson%20syndrome%20and%20toxic%20epidermal%20necrolysis%20using%20the%20Japanese%20Adverse%20Drug%20Event%20Report%20database&rft.jtitle=Journal%20of%20pharmaceutical%20health%20care%20and%20sciences&rft.au=Abe,%20Junko&rft.date=2016-06-21&rft.volume=2&rft.issue=1&rft.spage=14&rft.epage=14&rft.pages=14-14&rft.artnum=14&rft.issn=2055-0294&rft.eissn=2055-0294&rft_id=info:doi/10.1186/s40780-016-0048-5&rft_dat=%3Cgale_pubme%3EA469989146%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1800799814&rft_id=info:pmid/27330825&rft_galeid=A469989146&rfr_iscdi=true |